P Grosclaude1, A Belot2, L Daubisse Marliac3, L Remontet2, N Leone4, N Bossard2, M Velten5. 1. UMR1027, université de Toulouse III, 31062 Toulouse, France; IUC, Registre des cancers du Tarn, 31300 Toulouse, France. Electronic address: pascale.grosclaude@inserm.fr. 2. Service de biostatistique, hospices civils de Lyon, centre hospitalier Lyon-Sud, 69424 Lyon, France; Université de Lyon-I, 69622 Villeurbanne, France; CNRS, UMR 5558, laboratoire biostatistique santé, 69495 Pierre-Bénite cedex, France. 3. UMR1027, université de Toulouse III, 31062 Toulouse, France; IUC, Registre des cancers du Tarn, 31300 Toulouse, France. 4. Registre des cancers du Limousin, 87000 Limoges, France. 5. EA 3430, registre des cancers du Bas-Rhin, laboratoire d'épidémiologie et de santé publique, faculté de médecine, université de Strasbourg, 67085 Strasbourg, France.
Abstract
UNLABELLED: The prostate cancer became for two decades the most frequent cancer in men. We describe the evolution of its incidence and mortality from 1980 to 2011 for France. METHODS: Incidence data were collected from registries and national incidence estimates were based on the use of mortality as a correlate of incidence. RESULTS: After a very strong increase of incidence between 1980 (24.8/100,000) and 2005 (124.5/100,000), we observe a net decline since (97.7/100,000, in 2011). The reduction began earlier for the old patients. The evolution of mortality is very different. We observe a regular reduction since the end of 1990s (from 18.0/100,000 in 1990 to 10.5/100,000 in 2011). The reduction began earlier for the young patients. CONCLUSION: This pattern of evolution is observed in all the countries where the use of the PSA had caused an important increase of the diagnosis of prostate cancer. LEVEL OF EVIDENCE: 3.
UNLABELLED: The prostate cancer became for two decades the most frequent cancer in men. We describe the evolution of its incidence and mortality from 1980 to 2011 for France. METHODS: Incidence data were collected from registries and national incidence estimates were based on the use of mortality as a correlate of incidence. RESULTS: After a very strong increase of incidence between 1980 (24.8/100,000) and 2005 (124.5/100,000), we observe a net decline since (97.7/100,000, in 2011). The reduction began earlier for the old patients. The evolution of mortality is very different. We observe a regular reduction since the end of 1990s (from 18.0/100,000 in 1990 to 10.5/100,000 in 2011). The reduction began earlier for the young patients. CONCLUSION: This pattern of evolution is observed in all the countries where the use of the PSA had caused an important increase of the diagnosis of prostate cancer. LEVEL OF EVIDENCE: 3.